Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by toinv261on Dec 20, 2016 12:53pm
136 Views
Post# 25625392

BETonMACE trial quality

BETonMACE trial qualityI was just reading a couple of BDAZ's posts on Agora regarding the countries where the BETonMACE trial is happening.

I have little doubt that high quality science takes place throughout the world. However, as I looked at the countries involved it sort of raises the question of quality control of the trial. I recall reading posts about issues on the ASSURE trial. I also recall reading about the quality and expertise of the BETonMACE steering committee and felt reassured.

Does anyone have any POVs regarding quality control of the BETonMACE trial?

Also, I noted the paucity of comments after the AGMs/updates and just now read posts and, although I never want to speak for others, I do feel there has been a very large collective let down caused by Don's failure to deliver on the licensing deal (and I guess subsequently his very poor, non informative RVX update).

Great science continues at RVX and Zenith IMHO. Very poor performance on the business side in 2016. I'll continue to hope for 2017 or at least 2018.

Thanks
Toinv 
Bullboard Posts